PF-03715455
Modify Date: 2024-04-06 09:22:50
PF-03715455 structure
|
Common Name | PF-03715455 | ||
|---|---|---|---|---|
| CAS Number | 1056164-52-3 | Molecular Weight | 700.27300 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C35H34ClN7O3S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PF-03715455PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease)[1][2]. |
| Name | 1-[5-tert-butyl-2-(3-chloro-4-hydroxyphenyl)pyrazol-3-yl]-3-[[2-[[3-[2-(2-hydroxyethylsulfanyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-6-yl]sulfanyl]phenyl]methyl]urea |
|---|---|
| Synonym | More Synonyms |
| Description | PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease)[1][2]. |
|---|---|
| Related Catalog | |
| Target |
p38α:0.88 nM (IC50) p38β:23 nM (IC50) |
| In Vitro | PF-03715455 is a moderate inhibitor of CYP1A2, CYP2C19, and CYP2D6 and a potent inhibitor of CYP’s 2C9 and CYP3A4[2]. |
| In Vivo | PF-03715455 treatment shows that the Vss and T1/2 are 0.19 L/kg, 1 hour, respectively[2]. Animal Model: Male CD Sprague Dawley rats (300-450 g)[2] Dosage: 1 mg/kg Administration: I.v. (Pharmacokinetic Analysis) Result: The Vss, and T1/2 were 0.19 L/kg, 1 hour, respectively. |
| References |
| Molecular Formula | C35H34ClN7O3S2 |
|---|---|
| Molecular Weight | 700.27300 |
| Exact Mass | 699.18500 |
| PSA | 183.69000 |
| LogP | 8.07320 |
| 2yis |
| UNII-0TJ631J0KP |
| PF-03715455 |